New! View global litigation for patent families

US5389379A - Process for the preparation of biologically active material containing polymeric microcapsules - Google Patents

Process for the preparation of biologically active material containing polymeric microcapsules Download PDF

Info

Publication number
US5389379A
US5389379A US08017925 US1792593A US5389379A US 5389379 A US5389379 A US 5389379A US 08017925 US08017925 US 08017925 US 1792593 A US1792593 A US 1792593A US 5389379 A US5389379 A US 5389379A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
solvent
process
non
polymer
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08017925
Inventor
Cardina A. M. C. Dirix
Hendrikus J. M. Kamp
Anthonius P. Sam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

A process for the preparation of microcapsules containing biologically active material is disclosed. The process involves dissolving a polymer into a solvent into which the active material is also introduced; atomizing the resulting suspension or solution and collecting the droplets in a non-solvent for the polymeric droplets containing active material, resulting in coagulation. Subsequently, the coagulated droplets are hardened in a second non-solvent.

Description

FIELD

The invention relates to a process for the preparation of biologically active agent containing polymeric microcapsules, which process involves dissolving a polymer into a solvent into which the active material is also introduced and forming droplets therefrom from which the solvent is subsequently removed.

STATE OF THE ART

A similar process is described in EP 301 969A1 (corresponding to U.S. Pat. No. 4,897,267) with the droplets being formed by emulsification of the active material containing polymer solution in a medium, usually mineral oil, which is not miscible with the solvent. The droplets are freed from the solvent by evaporation, after which a suspension of polymeric particles is obtained. Emulsification is also the principle of the process described in FR-A-2 491 351. In this process microcapsules are prepared by emulsifying active material and a polymer--both dissolved or dispersed in a solvent, for example dichloromethane--in an aqueous solution, after which the solvent is partly evaporated and further washed out through filtration, extraction and washing with water. Hardening occurs slowly during the process of evaporation and extraction. A disadvantage of this method is that it can only be applied batch-wise and that clotting of the filter can seriously hamper the process. A drawback to emulsification methods in general is the limited choice one has for the polymer solvent, a sufficiently soluble non-aqueous medium which must be volatile. Another drawback is that, upon emulsification of the polymer solution, the active material it contains may end up in the dispersion medium rather than in the polymer solution droplets. Further, such processes are not easily up-scaled.

Another process for making microspheres from Nukem GmbH of Alzenau, Germany is somewhat described in C.E. vol. 97 (November 1990). The spheres are produced by means of an injection moulding process from an initial liquid phase which is a fusion, suspension or solution. The liquid phase is passed through nozzles of a chosen diameter. The nozzle head is oscillated at intervals to interrupt the liquid phase flow resulting in homogeneously sized drops. The drops fall through a "reaction zone" where an undescribed coagulation process is initiated. Thereafter the microspheres are further shaped by an undescribed chemical reaction with a gas or liquid phase. The entire process is complicated and not very well described.

A different process for making microcapsules is atomizing a polymer solution into which solution the active material is also introduced, and subsequently removing the solvent from the droplets. Such a method is described in WO-A-9 013 780. In this method, the polymer/active agent mixture is atomized into a vessel containing a liquid non-solvent, alone or frozen and overlayered with a liquified gas, at a temperature below the freezing point of the polymer/active agent solution. The cold liquified gas or liquid immediately freezes the polymer droplets. As the droplets and the non-solvent for the polymer are warmed, the solvent in the droplets thaws and is extracted into the non-solvent, resulting in hardened microspheres. Drawbacks of this hardening method are the low temperature and long reaction time necessary for obtaining uniform spherical non-aggregated polymeric microsheres. Therefore, this method is unattractive for large scale production.

It would be an improvement in the art to have a relatively simple and straight-forward process for making microcapsules.

SUMMARY OF THE INVENTION

The invention provides a process for the preparation of polymeric microcapsules containing a biologically active agent which process is efficiently upscalable. The polymer solution droplets are formed by atomization in such a manner that the droplets contain the active material. These droplets are collected and coagulated in a non-solvent. The invention includes a process of the aforementioned type characterized in that the coagulated droplets are subsequently transferred into a second non-solvent.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts the release of estradiol from microcapsule prepared according to the invention.

FIG. 2 depicts the release of the hexapeptide H-Gly-Gly-Phe-Met(O2)-D-Lys-Phe-OH (a β-endorphin 62-67 derivative) from microcapsule prepared according to the invention.

FIG. 3 depicts the release of the hexapeptide Org 2766 (H-Met(O)2 -Glu-His-Phe-D-Lys-Phe-OH) from microcapsules prepared according to the invention.

FIG. 4 depicts the release rate of bovine serum albumin from microcapsules prepared according to the invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Of course, the extent to which a liquid medium functions as a solvent or a non-solvent is dependent on the polymer type and biologically active material chosen. The artisan generally knows which solvent to use with which polymer and which non-solvent. Employing such knowledge, the process is essentially a fast and simple method for preparing polymeric microcapsules, especially microcapsules for in vivo use. The solvent and/or non-solvent may consist of a mixture of solvents and non-solvents.

Preferentially, both the polymer and the biologically active agent will be soluble in the chosen solvent at the temperature used during the atomization process. Also, preferentially, neither the polymer nor the biologically active material will be soluble in the selected non-solvent at the relevant process temperature. The solvent may also contain some non-solvent, so long as the concentration of such non-solvent is sufficiently low so as not to affect detrimentally the solubility of the biologically active agent or agents in the solvent.

Solubilities of various biologically active materials are given in, for example, Gennaro et al., Remington's Pharmaceutical Sciences, (Mack Publishing Co. 18th ed. 1990), and The Merck Index, (11th ed. 1989). Solubilities of various polymers are also available in various well-known texts.

Especially with regard to controlled release behaviour, parameters like particle size and particle size distribution are of importance. In preparing biologically active agent-containing microcapsules, the required values for these parameters, and therefore also the process conditions are determined by release-studies. A general rule, applicable to all polymers and all biologically active substances cannot be given.

In a previously described process (i.e. that disclosed in EP 301,969 and in FR-A-2 491 351) the parameters are determined by the emulsifying step, e.g. by the manner in which stirring is carried out. As is commonly known in the art, such a step should be adapted upon upscaling, of which the impact on surface and the impact on volume are different. In this respect, such a process is disadvantageous, since upscaling will lead to different results than those attained on a small scale, and new release studies will be needed.

In view of the above mentioned drawbacks, atomization methods are advantageous. After the process conditions have been determined, process upscaling can be effected simply by increasing the number of atomizing nozzles and by using a larger collecting capacity. In this way, the crucial step of forming the droplets in the atomization process is not affected by upscaling.

"Atomizing" may be accomplished by commercially available atomizers. Commercially available atomizers are also used to humidify air or goods, to inject gas into liquids, and to degas liquids. By using the term "atomizing", within the field of spraying liquids, it is clear that droplets are formed having a size of about 10-1000 μm, which size also indicates that the particles formed should be called "microcapsules". Of course, the droplet's size, which directly determines the particle size, can be tuned by adjusting the atomizer.

In this respect it is preferred to use an ultrasonic atomizer, which permits easy adjustment of particle size by varying the oscillation frequency. Ultrasonic atomizers are marketed, for example, by Lechler and are described in the technical information bulletin which accompanies the atomizer.

In the instant process, the droplets formed by ultrasonic atomization are first collected in a non-solvent. In this first step, the droplets remain intact, coagulate and some polymer solvent is extracted into the non-solvent. Subsequently, the first non-solvent is exchanged by a second non-solvent for hardening the microspheres.

The process according to the present invention may be applied to all polymers, provided that a suitable solvent and suitable non-solvent exist. A solvent can be regarded as suitable if the viscosity of the polymer solution can be kept low enough for the solution to be atomized. A non-solvent can be used in the collection step if the droplets remain intact, which means that polymeric films floating on the non-solvent are not formed and deformation or aggregation of the coagulated droplets is not observed. A non-solvent for the hardening step can be used if both the polymer solvent and the non-solvent of the collecting- and coagulating step are extracted by it and if the polymer hardens in this solvent. Conditions leading to favourable results should be determined per polymer type.

Polymers and co-polymers which are used as carrier medium for injectable controlled release dosage forms for therapeutics generally are biologically degradable. Preferably the polymer or co-polymer will contain bonds which can be hydrolysed to form non-toxic degradation products. Examples of such polymers include poly(glycolic acid), poly(lactic acid), copolymers of glycolic acid and L-lactic acid, gelatin, agar, starch, arabinogalactan, albumin, collagen, natural or synthetic materials or polymers, such as poly(ε-caprolactone), poly(ε-caprolactone-lactic acid ketone), poly(ε-caprolactone-glycolic acid ketone), poly(β-hydroxybutyric acid), polyethylene oxide, polyethylene, poly(alkyl-2-cyanoacrylate), hydrogels such as poly(hydroxyethyl methacrylate) or block copolyether-esters, polyamides, e.g., poly(acrylamides), poly(amino acids)(i.e. L-leucine, L-aspartic acid, β-methyl-L-aspartate, β-benzyl-L-aspartate, glutamic acid and the like), poly(2-hydroxy-ethyl-DL-aspartamide), poly(ester urea), poly(L-phenyl-alanine/ethyleneglycol/1,6-diisocyanato-hexane), poly(methylmethacrylate), poly-phosphazenes, polymers and copolymers of poly(hydroxybutyrate) and poly(hydroxyvalerate), poly(orthoesters), poly(orthocarbonates), poly(anhydrides), poly(alkyl-α-cyanoacrylates), poly(urethanes), poly(depsipeptides) and aliphatic polyesters.

Polymers of glycolic acid, lactic acid and copolymers of glycolic and lactic acid (PLAGA) are preferred. In the present field this preference is common, due to the good biocompatibility and release behaviour of these polymers. A further advantage to these polymers is their solubility in acetone, which to a certain extent is biocompatible. A preferred solvent for use with PLAGA is acetone, preferred first non-solvents for use with PLAGA are ethanol, water, and mixtures thereof. A preferred second non-solvent is water.

A further advantage of the invention is that it can be carried out at ambient temperature.

In the above-cited EP 0 301 969, the polylactide used is also dissolved in acetone, but due to the required evaporation of the solvent a heavier oil is needed to collect the polymer solution droplets, which eventually will lead to the polymeric microcapsules being contaminated. In using the commonly preferred polymers of lactic and glycolic acid a preferred embodiment of the process according to the invention has the further advantage that the polymeric microcapsules may be obtained in water, which is a strong non-solvent for those polymers and will not leave any contamination on the microcapsules. By virtue of the following general procedure, in fact all polymers for which water acts as a strong non-solvent can eventually be collected in water.

The general procedure according to the preferred embodiment of the present invention comprises using a medium which acts as a suitable non-solvent for the polymer to collect the atomized droplets and, after a residence time of several minutes to a few hours, transferring the particles to water. Directly collecting the atomized droplets of PLAGA in water generally will lead to a thin polymeric film on the water surface instead of microcapsules being formed. Specifically applied to the above preferred polymers, the atomized polymer solution droplets are first collected in ethanol. Hardening of the microcapsules in ethanol at ambient pressure and temperature is not possible; it inevitably leads to aggregation of the microparticles and/or gelation of PLAGA on the long term. Surface active agents may be added to the non-solvent during extraction of the (polymer) solvent to reduce the possibility of aggregation of the microcapsules.

In the presently most preferred embodiment, the microcapsules, as collected in the non-solvent, are vibrated loose by means of ultrasonic vibration.

As used herein, "a biologically active agent" is a substance having pharmacological or physiological effect. Microcapsules containing such substances in particular find use in the controlled release of drugs.

Preferred biologically active materials are medicinal compounds, especially those intended for chronic administration. Such medicinal compounds include peptides, such as LHRH antagonists; steroids; proteins, such as growth hormone or insulin; cytostatics, oligosaccharides and polysaccharides.

For veterinary medicine they can be used to deliver a very wide range of active ingredients e.g. glucocorticoids, gestagens, adrenergic agents, β-blockers, sedatives, and vaccines (adjuvants).

They may also be used to deliver insecticides, herbicides, pheromones and "repellants" to a local environment.

The invention is further explained by reference to the following EXAMPLES.

EXAMPLE I

Procedure for manufacturing 10 g of estradiol loaded (5%) PLAGA microcapsules by the method according to the invention:

a. Dissolve 500 mg of estradiol in 10 g of acetone.

b. Dissolve 9.5 g of PLAGA in 30 ml of acetone.

c. Add the estradiol solution to the PLAGA solution and homogenize.

d. Atomize the estradiol/PLAGA solution with the Ultrasonic Atomizer US1 (Lechler).

e. Use 500 ml of ethanol as initial collection and coagulation medium.

f. Exchange after 1/2 hour the ethanol for the same volume of purified water.

g. Collect the hardened microcapsules after 1 hour by filtration.

h. Wash the microcapsules with purified water.

i. Dry the microcapsules at room temperature for 16 hours in vacuo.

j. Screen the microcapsule preparation through a 150 μm sieve.

EXAMPLE II

Peptide and protein loaded PLAGA microcapsules are prepared in the same way, except for the fact that the active agents are not dissolved, but suspended in the PLAGA acetone solution.

EXAMPLE III-VI

Release studies on microcapsules made according to the invention were carried out on microcapsules containing a steroid (FIG. 1); different oligopeptides (FIGS. 2 and 3); and a protein (FIG. 4).

References herein to specific examples or embodiments should not be constructed as limitations to the scope of the invention which is defined by the appended claims.

Claims (7)

We claim:
1. A process for the preparation of polymeric microcapsules comprising a biologically active agent, said process comprising mixing an active agent with a solvent to form a solution or suspension, dissolving a polymer in a solvent, which may be the same solvent used for dissolving or suspending the active agent, atomizing the formed solution or suspension, subsequently collecting the thus formed droplets in a non-solvent, and transferring the coagulated droplets into a second non-solvent.
2. The process according to claim 1, wherein the atomization process is ultrasonic atomization.
3. The process according to claim 1, wherein the polymer is biodegradable.
4. The process according to claim 1, wherein the polymer is a copolymer of lactic acid and glycolic acid.
5. The process according to any claim 1, wherein the second non-solvent is water.
6. The process according to claim 1, wherein the polymer is dissolved in acetone, the first non-solvent is ethanol or an ethanol-water mixture, and the second non-solvent is water.
7. The process according to claim 1, wherein the solution or suspension to be atomized comprises a non-solvent in an amount sufficiently small that it does not affect the solubility of the active agent.
US08017925 1992-02-18 1993-02-16 Process for the preparation of biologically active material containing polymeric microcapsules Expired - Fee Related US5389379A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP92200466 1992-02-18
EP92200466 1992-02-18

Publications (1)

Publication Number Publication Date
US5389379A true US5389379A (en) 1995-02-14

Family

ID=8210436

Family Applications (1)

Application Number Title Priority Date Filing Date
US08017925 Expired - Fee Related US5389379A (en) 1992-02-18 1993-02-16 Process for the preparation of biologically active material containing polymeric microcapsules

Country Status (8)

Country Link
US (1) US5389379A (en)
EP (1) EP0556917B1 (en)
JP (1) JPH05337360A (en)
CA (1) CA2089354A1 (en)
DE (2) DE69302721D1 (en)
DK (1) DK0556917T3 (en)
ES (1) ES2090836T3 (en)
FI (1) FI930672A (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
WO1996040076A1 (en) * 1995-06-07 1996-12-19 Emisphere Technologies, Inc. Spray drying method and apparatus
US5601846A (en) 1992-06-15 1997-02-11 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5766633A (en) 1993-04-22 1998-06-16 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5811127A (en) 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5824345A (en) 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5958457A (en) 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5972387A (en) 1992-12-21 1999-10-26 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6071510A (en) 1995-03-31 2000-06-06 Emisphere Technologies, Inc. Modified amino acids and compositions comprising the same for delivering active agents
US6084112A (en) 1995-09-11 2000-07-04 Emisphere Technologies, Inc. Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US6100285A (en) 1995-06-07 2000-08-08 Emisphere Technologies, Inc. Method of solubilizing itraconazole
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US6242495B1 (en) 1997-02-07 2001-06-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US6375983B1 (en) 1996-06-14 2002-04-23 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US6391303B1 (en) 1996-11-18 2002-05-21 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US6663887B2 (en) 1993-04-22 2003-12-16 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20030230819A1 (en) * 2000-12-13 2003-12-18 Kinam Park Microencapsulation using ultrasonic atomizers
US20050147567A1 (en) * 1999-10-29 2005-07-07 Kuo Mei-Chang Compositions comprising an active agent
US20050186176A1 (en) * 1996-03-29 2005-08-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060134130A1 (en) * 1993-04-22 2006-06-22 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US20060166859A1 (en) * 1997-02-07 2006-07-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20070031611A1 (en) * 2005-08-04 2007-02-08 Babaev Eilaz P Ultrasound medical stent coating method and device
US20070051307A1 (en) * 2005-08-16 2007-03-08 Babaev Eilaz P Ultrasound apparatus and methods for mixing liquids and coating stents
WO2007070957A1 (en) * 2005-12-21 2007-06-28 Monash University Process and apparatus for generating particles
US20080041532A1 (en) * 2006-08-07 2008-02-21 Industrial Technology Research Institute System for fabricating nanoparticles
US20080054091A1 (en) * 2005-08-04 2008-03-06 Bacoustics Llc Ultrasonic atomization and/or seperation system
US20080142616A1 (en) * 2006-12-15 2008-06-19 Bacoustics Llc Method of Producing a Directed Spray
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383470B1 (en) 1992-09-26 2002-05-07 Thomas Fritzsch Microparticle preparations made of biodegradable copolymers
CN1055417C (en) * 1995-09-05 2000-08-16 中国科学院成都有机化学研究所 Nucleus-shell structure protein high-molecule microball and its manufacturing method
CN1626243A (en) 1996-04-23 2005-06-15 爱尔兰伊普森制造有限公司 Sustained release ionic conjugate
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491351A1 (en) * 1980-10-06 1982-04-09 Stolle Res & Dev Process for microcapsulation
US4897267A (en) * 1987-07-30 1990-01-30 Ire-Celltarg S.A. Microparticles comprising a biodegradable polymer controlling the release of an antimalaria active principle, pharmaceutical compositions comprising it and process for its preparation
WO1990013780A1 (en) * 1989-05-01 1990-11-15 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2491351A1 (en) * 1980-10-06 1982-04-09 Stolle Res & Dev Process for microcapsulation
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4897267A (en) * 1987-07-30 1990-01-30 Ire-Celltarg S.A. Microparticles comprising a biodegradable polymer controlling the release of an antimalaria active principle, pharmaceutical compositions comprising it and process for its preparation
WO1990013780A1 (en) * 1989-05-01 1990-11-15 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.E., vol. 97 (Nov., 1990). *
Sefton et al., Journal of Pharaceutical Sciences, "Ethylene-Vinyl Acetate Copolymer Microspheres for Controlled Release of Macromolecules", vol. 73, No. 12, Dec., 1984.
Sefton et al., Journal of Pharaceutical Sciences, Ethylene Vinyl Acetate Copolymer Microspheres for Controlled Release of Macromolecules , vol. 73, No. 12, Dec., 1984. *

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6071538A (en) 1992-06-15 2000-06-06 Emisphere Technologies, Inc. Oral delivery composition comprising supramolecular complex
US5601846A (en) 1992-06-15 1997-02-11 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5811127A (en) 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US6348207B1 (en) 1992-06-15 2002-02-19 Emisiphere Technologies, Inc. Orally deliverable supramolecular complex
US6245359B1 (en) 1992-06-15 2001-06-12 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US6413550B1 (en) 1992-06-15 2002-07-02 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5840340A (en) 1992-06-15 1998-11-24 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5972387A (en) 1992-12-21 1999-10-26 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5766633A (en) 1993-04-22 1998-06-16 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US6663887B2 (en) 1993-04-22 2003-12-16 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20040068013A1 (en) * 1993-04-22 2004-04-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060134130A1 (en) * 1993-04-22 2006-06-22 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US6100298A (en) 1993-04-22 2000-08-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5958457A (en) 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5955503A (en) 1993-04-22 1999-09-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US6180140B1 (en) 1994-04-22 2001-01-30 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5935601A (en) * 1994-04-22 1999-08-10 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5976569A (en) 1994-09-29 1999-11-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US6346242B1 (en) 1995-03-31 2002-02-12 Emishpere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6428780B2 (en) 1995-03-31 2002-08-06 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6071510A (en) 1995-03-31 2000-06-06 Emisphere Technologies, Inc. Modified amino acids and compositions comprising the same for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US6051258A (en) 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US6461545B1 (en) 1995-06-07 2002-10-08 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US5667806A (en) 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US6100285A (en) 1995-06-07 2000-08-08 Emisphere Technologies, Inc. Method of solubilizing itraconazole
US5824345A (en) 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
WO1996040076A1 (en) * 1995-06-07 1996-12-19 Emisphere Technologies, Inc. Spray drying method and apparatus
US6084112A (en) 1995-09-11 2000-07-04 Emisphere Technologies, Inc. Method for preparing ω-aminoalkanoic acid derivatives from cycloalkanones
US20050186176A1 (en) * 1996-03-29 2005-08-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6375983B1 (en) 1996-06-14 2002-04-23 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US6391303B1 (en) 1996-11-18 2002-05-21 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6242495B1 (en) 1997-02-07 2001-06-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US8686154B2 (en) 1997-02-07 2014-04-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20090324540A1 (en) * 1997-02-07 2009-12-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060166859A1 (en) * 1997-02-07 2006-07-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6361798B1 (en) 1998-10-28 2002-03-26 Oakwood Laboratories, L.L.C. Method and apparatus for formulating microspheres and microcapsules
USRE39592E1 (en) * 1998-12-31 2007-04-24 Intervet Inc. Extended release growth promoting two component composition
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
US7482024B2 (en) 1999-10-29 2009-01-27 Nektar Therapeutics Compositions comprising an active agent
US20090117193A1 (en) * 1999-10-29 2009-05-07 Nektar Therapeutics Compositions Comprising an Active Agent
US20050147567A1 (en) * 1999-10-29 2005-07-07 Kuo Mei-Chang Compositions comprising an active agent
US8501240B2 (en) 1999-10-29 2013-08-06 Novartis Ag Compositions comprising an active agent
US20030230819A1 (en) * 2000-12-13 2003-12-18 Kinam Park Microencapsulation using ultrasonic atomizers
US6767637B2 (en) 2000-12-13 2004-07-27 Purdue Research Foundation Microencapsulation using ultrasonic atomizers
US9101949B2 (en) 2005-08-04 2015-08-11 Eilaz Babaev Ultrasonic atomization and/or seperation system
US20070031611A1 (en) * 2005-08-04 2007-02-08 Babaev Eilaz P Ultrasound medical stent coating method and device
US20080054091A1 (en) * 2005-08-04 2008-03-06 Bacoustics Llc Ultrasonic atomization and/or seperation system
US7896539B2 (en) 2005-08-16 2011-03-01 Bacoustics, Llc Ultrasound apparatus and methods for mixing liquids and coating stents
US20070051307A1 (en) * 2005-08-16 2007-03-08 Babaev Eilaz P Ultrasound apparatus and methods for mixing liquids and coating stents
WO2007070957A1 (en) * 2005-12-21 2007-06-28 Monash University Process and apparatus for generating particles
US20080041532A1 (en) * 2006-08-07 2008-02-21 Industrial Technology Research Institute System for fabricating nanoparticles
US20080142616A1 (en) * 2006-12-15 2008-06-19 Bacoustics Llc Method of Producing a Directed Spray
US7753285B2 (en) 2007-07-13 2010-07-13 Bacoustics, Llc Echoing ultrasound atomization and/or mixing system
US7780095B2 (en) 2007-07-13 2010-08-24 Bacoustics, Llc Ultrasound pumping apparatus

Also Published As

Publication number Publication date Type
CA2089354A1 (en) 1993-08-19 application
FI930672A (en) 1993-08-19 application
EP0556917A1 (en) 1993-08-25 application
FI930672A0 (en) 1993-02-16 application
JPH05337360A (en) 1993-12-21 application
DK0556917T3 (en) 1996-09-16 grant
DE69302721T2 (en) 1996-09-19 grant
ES2090836T3 (en) 1996-10-16 grant
DE69302721D1 (en) 1996-06-27 grant
FI930672D0 (en) grant
EP0556917B1 (en) 1996-05-22 grant

Similar Documents

Publication Publication Date Title
Cohen et al. Controlled delivery systems for proteins based on poly (lactic/glycolic acid) microspheres
US6699500B2 (en) Sustained-release preparation capable of releasing a physiologically active substance
Putney et al. Improving protein therapeutics with sustained-release formulations
US5916598A (en) Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5271961A (en) Method for producing protein microspheres
US5631020A (en) Method for producing microcapsule
US5648095A (en) Preparation of microparticles
Freitas et al. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology
US5759563A (en) Liquid delivery compositions
US5759582A (en) Controlled release of pharmaceutically active substances from coacervate microcapsules
US6436443B2 (en) Porous particles comprising excipients for deep lung delivery
US5679377A (en) Protein microspheres and methods of using them
Park et al. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (D, L-lactic acid-co-glycolic acid) microspheres
US5989463A (en) Methods for fabricating polymer-based controlled release devices
Randolph et al. Sub‐micrometer‐sized biodegradable particles of poly (L‐lactic acid) via the gas antisolvent spray precipitation process
Bodmeier et al. Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. II. Some process parameters influencing the preparation and properties of microspheres
US5723269A (en) Microparticle preparation and production thereof
Herrmann et al. Somatostatin containing biodegradable microspheres prepared by a modified solvent evaporation method based on W/O/W-multiple emulsions
US5413797A (en) Controlled release ACTH containing microspheres
Bezemer et al. Microspheres for protein delivery prepared from amphiphilic multiblock copolymers: 1. Influence of preparation techniques on particle characteristics and protein delivery
US5981474A (en) Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same
US5993805A (en) Spray-dried microparticles and their use as therapeutic vehicles
US6511749B1 (en) Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US20050084533A1 (en) Polymer composite with internally distributed deposition matter
US20030026844A1 (en) Injectable sustained release pharmaceutical composition and processes for preparing the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: AKZO N.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARDINA A.M.C. DIRIX;KAMP, J.M. HENDRICKUS;REEL/FRAME:006543/0681

Effective date: 19930426

Owner name: AKZO N.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAM, ANTHONIUS P.;REEL/FRAME:006537/0984

Effective date: 19930503

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Expired due to failure to pay maintenance fee

Effective date: 19990214

AS Assignment

Owner name: AKZO NOBEL N.V., NETHERLANDS

Free format text: CHANGE OF NAME;ASSIGNOR:AKZO N.V.;REEL/FRAME:019767/0648

Effective date: 19940225

AS Assignment

Owner name: N.V. ORGANON, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AKZO NOBEL N.V.;REEL/FRAME:019773/0306

Effective date: 20070828